Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 MilliporeSigma Invests $76M to Expand Bioconjugation Facility in Missouri | Contract Pharma

What are you searching for?

Sign in
Breaking News

MilliporeSigma Invests $76M to Expand Bioconjugation Facility in Missouri

Will grow its ADC manufacturing capabilities and triple existing capacity.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, is investing $76 million to expand its ADC manufacturing capabilities and capacity at its Bioconjugation Center of Excellence facility in St. Louis, Missouri.
 
This investment will triple existing capacity and enhance the company’s contract development and manufacturing organization (CDMO) offering, reinforcing its commitment to clients and patients.
 
With additional capacity and by scaling utilities and enhancing Process and Analytical Development (PAD) labs, MilliporeSigma aims to provide industry-leading support for early-stage and commercial bioconjugates. The company’s goal is to ensure clients can bring their innovations to market more effectively and with shorter turnaround times.
 
“We are shaping tomorrow’s cancer care, today. With this investment, we are not just enhancing our capabilities; we are investing in our clients’ success by accelerating innovation and development to ultimately deliver novel therapies to patients more quickly,” said Benjamin Hein, Head of Life Science Services, Life Science business of Merck KGaA, Darmstadt, Germany. “ADCs represent a transformative approach to oncology, enabling targeted therapies that minimize damage to healthy tissues. As the market for this novel modality grows and the medical community adopts them as first-line treatments, it may mean that fewer patients need invasive treatments like chemotherapy and radiation that cause significant side effects.”
 
The ADC capacity expansion project will:
 

  • Upgrade 34,000 square feet to benefit the Process and Analytical Development, Quality Control, Research and Development, Manufacturing, and Logistics departments.
  • Add new labs, a dedicated manufacturing buffer preparation facility, and a cold storage and a GMP-controlled room temperature (CRT) warehouse that will be located close to the existing facility.
 
Other recent investments from MilliporeSigma this year include:
 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics